Common use of 100 Additional Definitions Clause in Contracts

100 Additional Definitions. Each of the following definitions is set forth in the section of this Agreement indicated below: Definition: Section: Alliance Business-Development Manager 2.1 Alliance R&D Manager 2.2 Arbitration Request 16.2.1 Audited Party 9.10 Auditing Party 9.10 Bankruptcy Code 4.7 Breaching Party 14.2 Buy-In Amount 5.4.2(b)(iv) Buy-In Party 5.4.2(b)(ii) Clinical Supply Agreement 7.2.1 Co-Chairperson 2.7 Commercial Supply Agreement 7.2.2 Commercialization Plan 8.4 Commercializing Party 8.1 Confidential Information 11.1 De Minimis Overage Amount 5.5.2(a) Development Budget 5.3.1 Development Collaboration Proposal 5.4.2(b) Disclosing Party 11.1 Excess Overage Amount 5.5.2(a) Effective Date Preamble Existing Confidentiality Agreement 11.4 Global Development Plan 5.3.1 *** 16.2.3 IdRS Preamble *** 9.3.1 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Development Budget 5.5.2 Initiating Party 10.4.3 Inspected Party 6.3.2 JEC 2.4.1 Joint Patents 10.3.3(a) JRDC 2.6.1 JSC 2.5.1 License Grant Date 3.3.3(a) License Grant Fee 9.2 LLS Preamble Losses 13.1 M&A Event 16.4 MacroGenics Preamble *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. Definition: Section: MacroGenics Product Patents 10.3.1(a) Non-Arbitrable Dispute 16.1.2 Non-Breaching Party 14.2 Option 3.3.3(a) Option Grant Fee 9.1 Option Period 3.3.3(a) Party or Parties Preamble Project Director 2.3 Proposed Development Plan Amendment 5.4.2(a) Receiving Party 11.1 Reconciliation Payment 5.5.2(c) Research Program 3.1 Responsible Party 10.3.3(b) Royalty Term 9.5.2 SDEA Agreement 6.5.1 Servier Preamble Servier Product Patents 10.3.2(a) Supplemental Data 3.2.1

100 Additional Definitions. Each of the following definitions is set forth in the section of this Agreement indicated below: Definition: Section: Alliance Business-Development Manager 2.1 Alliance R&D Manager 2.2 Arbitration Request 16.2.1 Audited Party 9.10 Auditing Party 9.10 Bankruptcy Code 4.7 Breaching Party 14.2 Buy-In Amount 5.4.2(b)(iv) Buy-In Party 5.4.2(b)(ii) Clinical Supply Agreement 7.2.1 Co-Chairperson 2.7 Commercial Supply Agreement 7.2.2 Commercialization Plan 8.4 Commercializing Party 8.1 Confidential Information 11.1 De Minimis Overage Amount 5.5.2(a) Development Budget 5.3.1 Development Collaboration Proposal 5.4.2(b) Disclosing Party 11.1 Excess Overage Amount 5.5.2(a) Effective Date Preamble Existing Confidentiality Agreement 11.4 Global Development Plan 5.3.1 *** 16.2.3 IdRS Preamble *** 9.3.1 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Development Budget 5.5.2 Initiating Party 10.4.3 Inspected Party 6.3.2 JEC 2.4.1 Joint Patents 10.3.3(a) JRDC 2.6.1 JSC 2.5.1 License Grant Date 3.3.3(a) License Grant Fee 9.2 LLS Preamble Losses 13.1 M&A Event 16.4 MacroGenics Preamble *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. Definition: Section: MacroGenics Product Patents 10.3.1(a) Non-Arbitrable Dispute 16.1.2 Non-Breaching Party 14.2 Option 3.3.3(a) Option Grant Fee 9.1 Option Period 3.3.3(a) Party or Parties Preamble Project Director 2.3 Proposed Development Plan Amendment 5.4.2(a) Receiving Party 11.1 Reconciliation Payment 5.5.2(c) Research Program 3.1 Responsible Party 10.3.3(b) Royalty Term 9.5.2 SDEA Agreement 6.5.1 Servier Preamble Servier Product Patents 10.3.2(a) Supplemental Data 3.2.13.2.1 ARTICLE 2

100 Additional Definitions. Each of the following definitions is set forth in the section Section of this Agreement indicated below: Definition: Section: Definition Section Accounting Period 10.1 Alliance Business-Development Manager 2.1 Alliance R&D Manager 2.2 Arbitration Request 16.2.1 Audited Party 9.10 Auditing Party 9.10 Director 8.1 Bankruptcy Code 4.7 20 Breaching Party 14.2 18.2.1 Buy-In Amount 5.4.2(b)(iv) out Notice 9.4 Buy-In Party 5.4.2(b)(iiout Option 9.4 CEEP Start Date 18.3.2 Chugai 1.1 Company Meeting 1.78 Compound-Free Product 1.64 Compulsory Profit Share Percentage 9.3.8 Compulsory Sublicense 1.21 Compulsory Sublicensee 1.21 Core Patent Rights 1.30 Decision Period 13.4 EBI-031 1.32 Eleven Assigned Patent Rights 13.1.2 Eleven IND Clearance Activities 1.53 Eleven MTA Information 21.10 Eleven NDA Information 21.10 Eleven-Originated Transfer Activities 18.3.4.3 Excluded Roche Patent Rights 1.85 Expert Committee 9.3.3 Extended Roche GLP Tox Study Event 9.2 FDA-Required GLP Tox Study 1.53(a) Clinical Supply Agreement 7.2.1 CoFirst Buy-Chairperson 2.7 Commercial Supply Agreement 7.2.2 Commercialization Plan 8.4 Commercializing Party 8.1 Confidential Information 11.1 De Minimis Overage Amount 5.5.2(a) Development Budget 5.3.1 Development Collaboration Proposal 5.4.2(b) Disclosing Party 11.1 Excess Overage Amount 5.5.2(a) Effective Date Preamble Existing Confidentiality Agreement 11.4 Global Development Plan 5.3.1 *** 16.2.3 IdRS Preamble *** 9.3.1 out Option 9.4 FMI 1.1 - 18 - Definition Section HSR Act 14.1.5 Indemnified Party 13.3 15.3 Indemnifying Party 13.3 Initial Development Budget 5.5.2 15.3 Initiating Party 10.4.3 Inspected Party 6.3.2 JEC 2.4.1 Joint Patents 10.3.3(a) JRDC 2.6.1 JSC 2.5.1 License Grant Date 3.3.3(a) License Grant Fee 9.2 LLS Preamble Losses 13.1 M&A Event 16.4 MacroGenics Preamble *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. Definition: Section: MacroGenics Product Patents 10.3.1(a) Non-Arbitrable Dispute 16.1.2 13.4 Involuntary Termination 1.81 Minimum Transfer Payment 18.3.4.3 MTA 13.9 NDA 21.10 Non-Breaching Party 14.2 18.2.1 Non-Compound Active Agent 1.16 Patent Term Extensions 13.8 Payment Currency 10.3 Peremptory Notice Period 18.2.1 Primary Eleven Patent Rights 13.1.1 Redacted Agreement 17.4 Reference Product Sponsor 13.7 Relative Commercial Value 9.3.3 Representatives 19 Roche IND Clearance Activities 1.53 Roche Indemnitees 15.2 Roche Transfer Activities 18.3.4.3 Samples and PI Information 18.3.4.3 Second Buy-out Option 3.3.3(a9.4 Select Non-Prosecution Patent Rights 13.2 Sensitive Information 21.4(c) Option Grant Fee 9.1 Option Period 3.3.3(a) Party or Parties Preamble Project Director 2.3 Proposed Development Plan Amendment 5.4.2(a) Receiving Party 11.1 Reconciliation Payment 5.5.2(c) Research Program 3.1 Responsible Party 10.3.3(b) Royalty Term 9.5.2 SDEA Agreement 6.5.1 Servier Preamble Servier Product Patents 10.3.2(a) Supplemental Data 3.2.1Settlement 13.4 SPCs 13.8 Suit Notice 13.4 Voluntary Termination 1.81

100 Additional Definitions. Each of the following definitions is set forth in the section Section of this Agreement indicated below: Definition: Section: Definition Section Accounting Period 10.1 Alliance Business-Development Manager 2.1 Alliance R&D Manager 2.2 Arbitration Request 16.2.1 Audited Party 9.10 Auditing Party 9.10 Director 8.1 Bankruptcy Code 4.7 20 Breaching Party 14.2 18.2.1 Buy-In Amount 5.4.2(b)(iv) out Notice 9.4 Buy-In Party 5.4.2(b)(iiout Option 9.4 CEEP Start Date 18.3.2 Chugai 1.1 Company Meeting 1.78 Compound-Free Product 1.64 Compulsory Profit Share Percentage 9.3.8 Compulsory Sublicense 1.21 Compulsory Sublicensee 1.21 Core Patent Rights 1.30 Decision Period 13.4 EBI-031 1.32 Eleven Assigned Patent Rights 13.1.2 Eleven IND Clearance Activities 1.53 Eleven MTA Information 21.10 Eleven NDA Information 21.10 Eleven-Originated Transfer Activities 18.3.4.3 Excluded Roche Patent Rights 1.85 Expert Committee 9.3.3 Extended Roche GLP Tox Study Event 9.2 FDA-Required GLP Tox Study 1.53 (a) Clinical Supply Agreement 7.2.1 CoFirst Buy-Chairperson 2.7 Commercial Supply Agreement 7.2.2 Commercialization Plan 8.4 Commercializing Party 8.1 Confidential Information 11.1 De Minimis Overage Amount 5.5.2(a) Development Budget 5.3.1 Development Collaboration Proposal 5.4.2(b) Disclosing Party 11.1 Excess Overage Amount 5.5.2(a) Effective Date Preamble Existing Confidentiality Agreement 11.4 Global Development Plan 5.3.1 *** 16.2.3 IdRS Preamble *** 9.3.1 out Option 9.4 FMI 1.1 HSR Act 14.1.5 Indemnified Party 13.3 15.3 Indemnifying Party 13.3 Initial Development Budget 5.5.2 15.3 Initiating Party 10.4.3 Inspected Party 6.3.2 JEC 2.4.1 Joint Patents 10.3.3(a) JRDC 2.6.1 JSC 2.5.1 License Grant Date 3.3.3(a) License Grant Fee 9.2 LLS Preamble Losses 13.1 M&A Event 16.4 MacroGenics Preamble *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. Definition: Section: MacroGenics Product Patents 10.3.1(a) Non-Arbitrable Dispute 16.1.2 13.4 Involuntary Termination 1.81 Minimum Transfer Payment 18.3.4.3 MTA 13.9 NDA 21.10 Definition Section Non-Breaching Party 14.2 18.2.1 Non-Compound Active Agent 1.16 Patent Term Extensions 13.8 Payment Currency 10.3 Peremptory Notice Period 18.2.1 Primary Eleven Patent Rights 13.1.1 Redacted Agreement 17.4 Reference Product Sponsor 13.7 Relative Commercial Value 9.3.3 Representatives 19 Roche IND Clearance Activities 1.53 Roche Indemnitees 15.2 Roche Transfer Activities 18.3.4.3 Samples and PI Information 18.3.4.3 Second Buy-out Option 3.3.3(a9.4 Select Non-Prosecution Patent Rights 13.2 Sensitive Information 21.4 (c) Option Grant Fee 9.1 Option Period 3.3.3(a) Party or Parties Preamble Project Director 2.3 Proposed Development Plan Amendment 5.4.2(a) Receiving Party 11.1 Reconciliation Payment 5.5.2(c) Research Program 3.1 Responsible Party 10.3.3(b) Royalty Term 9.5.2 SDEA Agreement 6.5.1 Servier Preamble Servier Product Patents 10.3.2(a) Supplemental Data 3.2.1Settlement 13.4 SPCs 13.8 Suit Notice 13.4 Voluntary Termination 1.81